This exploratory analysis evaluated cumulative incidence rates (CIRs) of CNS and non-CNS progression in alectinib-treated patients in the pivotal phase II studies (Ou et al, 2016; Shaw et al, 2016) to determine to what extent alectinib may treat and/or control the spread of the disease in the CNS in ALK-positive NSCLC. Here, ALK is linked to non-small cell lung carcinoma.